Many manufacturers still treat Post-Market Surveillance (PMS) as a regulatory checkbox.
That approach doesn’t hold anymore.
Under the EU MDR, PMS is a structured and mandatory framework for all medical device classes. It requires continuous, proactive data collection and evaluation throughout the product lifecycle.
On the FDA side, the terminology may differ, and a formal “PMS Plan” is not always explicitly required. However, the expectation remains the same: continuous monitoring through complaint handling, CAPA, and adverse event reporting is essential.
So the question is no longer:
“Are we required to have a PMS system?”
The real question is:
“Is our PMS data actually being used or are we just storing it?”
How PMS Fails in Practice
Most post-market surveillance systems do not fail because of missing procedures or incomplete documentation. On paper, everything often looks compliant. The real problem is that PMS is disconnected from decision-making and real world usage.
In many organizations, PMS becomes a parallel activity rather than an integrated part of the product lifecycle. Data is collected, reports are generated, and obligations are formally met, but the information does not meaningfully influence what happens next.
A typical pattern looks like this:
- PMS operates in isolation from design and development activities
- Data is collected, but rarely translated into actionable insights
- Updates to risk management and clinical evaluation happen with significant delay
When PMS is disconnected in this way, it loses its primary purpose.
The consequence is not theoretical, it is practical:
Late signal detection → delayed corrective action → increased risk
By the time issues are formally escalated, opportunities for early mitigation have often already been missed.
What Regulators Actually Expect
Under EU MDR, PMS must be proactive, structured, and continuously updated, with clear links to risk management, clinical evaluation, and technical documentation.
FDA expects continuous monitoring through adverse event reporting, complaint handling, and, when needed, targeted studies.
Different frameworks, same expectation:
You must continuously monitor real-world performance and act on what you find
PMS Doesn’t Reduce Risk, Action Does
Let’s be precise. Post-Market Surveillance (PMS) itself does not reduce incidents; rather, it enables earlier signal detection, faster investigation, and timely corrective actions. It is these actions such as design changes, labeling updates, and field safety corrective actions that ultimately reduce recurrence and limit impact.
Without an effective PMS system in place, these actions are often delayed, increasing the risk that harm is not prevented in time.
What Good PMS Looks Like
Strong PMS systems are integrated into development and quality processes, continuously updated rather than periodic, and driven by data instead of documentation. Most importantly, they are designed to support real decision-making not just reporting.
If PMS outputs do not influence your risk management, clinical evaluation, or product improvements, the system is not delivering value. This is also clearly reflected in recent MDCG guidance, where PMS is expected to feed directly into core QMS processes and drive updates across the product lifecycle. In practice, this means traceability from data to analysis, from analysis to decisions, and from decisions to implemented changes.
At the same time, standardization efforts are ongoing to support manufacturers in building structured PMS systems, providing more practical guidance on how to integrate PMS into everyday quality and development workflows.
The Business Impact
When implemented properly, PMS becomes a business tool instead of just a regulatory requirement. It enables:
- Faster, more confident decisions
- Fewer surprises during audits and submissions
- Stronger credibility with regulators
- Real-world evidence that supports product strategy
- Reduced risk of safety issues through earlier detection and corrective action
Strong PMS helps protect what is often hardest to rebuild after a failure: trust.
Poor post-market oversight increases the risk of safety issues reaching patients and users, which can lead not only to regulatory consequences but also to significant damage to company reputation in public perception.
The goal is simple:
Turn PMS from a compliance task into a source of insight, risk control, and competitive advantage.
Final Thought and further reading
PMS is not about collecting data. It’s about acting on it fast enough to matter. A useful test is this:
Can you clearly show how post-market data changed at least one decision?
If the answer is no, there was no risk update, no clinical reassessment, and no design input, then PMS is likely underperforming, even if all required documents exist.
Treat PMS as a source of insight, not just an obligation, and you are better positioned to succeed in an increasingly data-driven regulatory environment.
Manufacturers who get this right don’t just stay compliant. They move faster, reduce risk, and build better products.
Further reading
- ISO/TR 20416:2020 – Post-market surveillance for manufacturers
- ISO 14971:2019 – Risk management for medical devices
- EU MDR (Regulation (EU) 2017/745), Articles 83–86
- MDCG 2025-10 – Guidance on Post-Market Surveillance
How Nometech can help?
If you’re unsure whether your PMS system is actually delivering value, it’s probably worth a closer look.
At Nometech, we help manufacturers close this gap by connecting post-market data directly to risk management, clinical evaluation, and design decision-making in a structured and compliant way.
More information about our services can be found at Medical Device Regulatory and Quality Services | Nometech.
Want to know if your PMS works in real life not just on paper?
Let’s book time and test it through an internal audit.